financetom
Business
financetom
/
Business
/
Why Are Linkers Industries Shares Falling On Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Are Linkers Industries Shares Falling On Friday?
Mar 20, 2026 8:51 AM

Linkers Industries Ltd ( LNKS ) shares are falling on Friday. The stock traded around 85 cents following a massive 51.36% jump during Thursday’s session.

Investors appear to be locking in profits after the stock closed Thursday at 88 cents.

• Linkers Industries ( LNKS ) stock is feeling bearish pressure. What’s behind LNKS decline?

SEC Filing Details Unit Offering

The price action follows a Form F-1 registration statement filed on Monday. Linkers Industries ( LNKS ) is offering up to 18.25 million ordinary units at approximately $0.9864 per unit.

Strategic Expansion in Southeast Asia

The company operates through its subsidiary, TEM Electronics in Malaysia. It recently expanded its footprint by acquiring 20% of LPW Electronics Co. in Thailand. This associated company owns a 6,500-square-meter production facility. Linkers plans to use the offering proceeds to potentially acquire further equity interests in LPW.

Technical Analysis

Linkers is trading 24.6% below its 20-day simple moving average (SMA), but 26.5% above its 100-day SMA, which signals short-term weakness while the intermediate trend remains intact.

Shares are up 21.95% over the past 12 months, and at current levels they're positioned closer to the 52-week low of 27 cents than the 52-week high of $1.68.

The RSI is at 47.10, which sits in neutral territory. Meanwhile, MACD is at -0.0537 versus a signal line at 0.0071.

Key Resistance: $1

Key Support: 50 cents

LNKS Stock Price Activity: Linkers Industries ( LNKS ) shares were down 4.51% at 84 cents at publication on Friday, according to Benzinga Pro data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
May 20, 2024
03:49 PM EDT, 05/20/2024 (MT Newswires) -- Rio Tinto (RIO) has declared force majeure on alumina shipments from its Queensland, Australia refineries due to gas shortages, Bloomberg reported Monday, citing people familiar with the situation. The company notified clients of the decision on Monday, the people told Bloomberg. The shortage has affected the mining company's Yarwun refinery and Queensland Alumina,...
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
May 20, 2024
03:33 PM EDT, 05/20/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Monday the phase 3 trial of its lung disease treatment Dupixent as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease, or COPD, met primary endpoint. The trial showed a 34% reduction in moderate or severe COPD exacerbations over...
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
May 20, 2024
03:42 PM EDT, 05/20/2024 (MT Newswires) -- Travis Boersma, 10% Owner, Director, Executive Chairman of Board, on May 16, 2024, sold 439,510 shares in Dutch Bros ( BROS ) for $16,235,448. Following the Form 4 filing with the SEC, Boersma has control over a total of 1,039,239 shares of the company, with 1,039,239 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1866581/000186658124000170/xslF345X03/wk-form4_1716233953.xml Price: 36.64,...
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
May 20, 2024
03:51 PM EDT, 05/20/2024 (MT Newswires) -- The independent lab that raised concerns about GSK's (GSK) Zantac heartburn medication has filed a whistleblower lawsuit against the UK drugmaker, alleging the company hid the drug's cancer risks for decades. The suit, filed in the US District Court for the Eastern District of Pennsylvania, by Valisure alleges GSK concealed data from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved